Table 2.
Serum paraoxonase activity and biochemical parameters in small cell lung cancer adenocarcinoma and epidermoid carcinoma patient groups
| SCLC (n = 9) | AC (n = 14) | EC (n = 16) | P value | |
| Total cholesterol (mg/dl) | 158.9 ± 30.7 | 170.9 ± 45.6 | 163.5 ± 63.1 | 0.849 |
| LDL cholesterol (mg/dl) | 115.4 ± 26.3 | 118.2 ± 41.1 | 114.4 ± 52.1 | 0.971 |
| HDL cholesterol (mg/dl) | 30.3 ± 4.3 | 34.2 ± 9.9 | 38 ± 31.3 | 0.680 |
| VLDL cholesterol (mg/dl) | 33.9 ± 15 | 27.8 ± 8.7 | 28.1 ± 11.6 | 0.504 |
| Triglyceride (mg/dl) | 158.8 ± 68.8 | 131.4 ± 37.1 | 140.1 ± 58.2 | 0.395 |
| PON1 (U/mL) | 233.9 ± 70.5 | 273.1 ± 118.1 | 245.4 ± 110.5 | 0.649 |
| ARE (U/L) | 163 ± 69.5 | 115.7 ± 44.2 | 142 ± 57.2 | 0.144 |
| PON1/ARE | 1.7 ± 0.9 | 2.5 ± 0.9 | 1.8 ± 0.7 | 0.062 |
Values are mean ± S.D. SCLC:Small Cell carcinoma, AC: Adenocarcinoma, EC:Epidermoid carcinoma, PON1: paraoxonase, ARE: arylesterase